Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.38 |
| ▸ | GHSR | Q92847 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33532816 | 0.91 | UCHL1 (0.39) | UCHL1GHSRIDO1KDM4EDDB1 | |
| SCHEMBL33531949 | 0.91 | ATM (0.38) | ATMUCHL1GHSRIDO1KDM4E | |
| SCHEMBL33531957 | 0.88 | UCHL1 (0.41) | UCHL1GHSRIDO1KDM4EDDB1 | |
| SCHEMBL33532197 | 0.85 | UCHL1 (0.51) | ATMUCHL1GHSRIDO1DDB1 | |
| SCHEMBL17681689 | 0.83 | UCHL1 (0.41) | UCHL1GHSRKDM4EDDB1CRBN | |
| SCHEMBL18765822 | 0.83 | UCHL1 (0.41) | UCHL1GHSRKDM4EDDB1CRBN | |
| SCHEMBL29676838 | 0.83 | UCHL1 (0.41) | UCHL1GHSRKDM4EDDB1CRBN | |
| SCHEMBL33530533 | 0.82 | UCHL1 (0.39) | UCHL1GHSRIDO1KDM4EDDB1 | |
| SCHEMBL33532324 | 0.81 | UCHL1 (0.41) | UCHL1KDM4EDDB1CRBNPOLB | |
| SCHEMBL30645340 | 0.80 | MTNR1B (0.46) | ATMGHSRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | ATM 3047/4885UCHL1 261/4885GHSR 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.